SN-38

CAT: 0804-HY-13704-01Size: 50 mgDry Ice: NoHazardous: No
CAT#:0804-HY-13704-01Size:50 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) [1][2][3][4][5].
CAS Number
[86639-52-3]
Product Name Alternative
7-Ethyl-10-hydroxycamptothecin
UNSPSC
12352005
Hazard Statement
H301
Target
ADC Payload; Autophagy; Drug Metabolite; Topoisomerase
Type
Natural Products
Related Pathways
Antibody-drug Conjugate/ADC Related; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/SN-38.html
Purity
99.94
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C2)=O
Molecular Formula
C22H20N2O5
Molecular Weight
392.40
Precautions
H301
References & Citations
[1]Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19 (6) :1493-8.|[2]Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56.|[3]Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51 (16) :4187-4191.|[4]Aaron T Jacobs, et al. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022 Oct:204:115209.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
Phase 2
Isoform
Camptothecins; Topo I

Popular Products